 | • レポートコード：MRC23Q36240 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の変形性関節症遺伝子治療市場について調査・分析し、世界の変形性関節症遺伝子治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（滑膜注射、軟骨注射）、用途別セグメント分析（病院/クリニック、整形外科センター、介護施設、老人ホーム、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Flexion、GeneQuine、Novartis、Smith & Nephew、Genascence、Kolon TissueGene、Sanofi、Paraxel、Medipost、Mundipharmaなどが含まれています。世界の変形性関節症遺伝子治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、変形性関節症遺伝子治療市場規模を推定する際に考慮しました。本レポートは、変形性関節症遺伝子治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、変形性関節症遺伝子治療に関するビジネス上の意思決定に役立てることを目的としています。 ・変形性関節症遺伝子治療市場の概要 - 変形性関節症遺伝子治療のタイプ別セグメント - 世界の変形性関節症遺伝子治療市場規模：タイプ別分析（滑膜注射、軟骨注射） - 変形性関節症遺伝子治療の用途別セグメント - 世界の変形性関節症遺伝子治療市場規模：用途別分析（病院/クリニック、整形外科センター、介護施設、老人ホーム、外来手術センター、その他） - 世界の変形性関節症遺伝子治療市場規模予測（2018年-2029年） ・変形性関節症遺伝子治療市場の成長トレンド - 変形性関節症遺伝子治療の地域別市場規模（2018年-2029年） - 変形性関節症遺伝子治療市場ダイナミクス - 変形性関節症遺伝子治療の業界動向 - 変形性関節症遺伝子治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：滑膜注射、軟骨注射 - 世界の変形性関節症遺伝子治療のタイプ別市場規模（2018年-2023年） - 世界の変形性関節症遺伝子治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院/クリニック、整形外科センター、介護施設、老人ホーム、外来手術センター、その他 - 世界の変形性関節症遺伝子治療の用途別市場規模（2018年-2023年） - 世界の変形性関節症遺伝子治療の用途別市場規模（2024年-2029年） ・変形性関節症遺伝子治療の地域別市場規模 - 北米の変形性関節症遺伝子治療市場規模（2018年-2029年） - アメリカの変形性関節症遺伝子治療市場規模（2018年-2029年） - ヨーロッパの変形性関節症遺伝子治療市場規模（2018年-2029年） - アジア太平洋の変形性関節症遺伝子治療市場規模（2018年-2029年） - 中国の変形性関節症遺伝子治療市場規模（2018年-2029年） - 日本の変形性関節症遺伝子治療市場規模（2018年-2029年） - 韓国の変形性関節症遺伝子治療市場規模（2018年-2029年） - インドの変形性関節症遺伝子治療市場規模（2018年-2029年） - オーストラリアの変形性関節症遺伝子治療市場規模（2018年-2029年） - 中南米の変形性関節症遺伝子治療市場規模（2018年-2029年） - 中東・アフリカの変形性関節症遺伝子治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Flexion、GeneQuine、Novartis、Smith & Nephew、Genascence、Kolon TissueGene、Sanofi、Paraxel、Medipost、Mundipharma ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Osteoarthritis Gene Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Osteoarthritis Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Osteoarthritis Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Osteoarthritis Gene Therapy in Hospitals and clinics is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Osteoarthritis Gene Therapy include Flexion, GeneQuine, Novartis, Smith & Nephew, Genascence, Kolon TissueGene, Sanofi, Paraxel and Medipost, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Osteoarthritis Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Osteoarthritis Gene Therapy.
The Osteoarthritis Gene Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Osteoarthritis Gene Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Osteoarthritis Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Flexion
GeneQuine
Novartis
Smith & Nephew
Genascence
Kolon TissueGene
Sanofi
Paraxel
Medipost
Mundipharma
Segment by Type
Synovium Injection
Cartilage Injection
Segment by Application
Hospitals and clinics
Orthopedic Centers
Assisted living Facilities
Nursing Homes
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Osteoarthritis Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Osteoarthritis Gene Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Synovium Injection
1.2.3 Cartilage Injection
1.3 Market by Application
1.3.1 Global Osteoarthritis Gene Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals and clinics
1.3.3 Orthopedic Centers
1.3.4 Assisted living Facilities
1.3.5 Nursing Homes
1.3.6 Ambulatory Surgical Centers
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Osteoarthritis Gene Therapy Market Perspective (2018-2029)
2.2 Osteoarthritis Gene Therapy Growth Trends by Region
2.2.1 Global Osteoarthritis Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Osteoarthritis Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Osteoarthritis Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Osteoarthritis Gene Therapy Market Dynamics
2.3.1 Osteoarthritis Gene Therapy Industry Trends
2.3.2 Osteoarthritis Gene Therapy Market Drivers
2.3.3 Osteoarthritis Gene Therapy Market Challenges
2.3.4 Osteoarthritis Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Osteoarthritis Gene Therapy Players by Revenue
3.1.1 Global Top Osteoarthritis Gene Therapy Players by Revenue (2018-2023)
3.1.2 Global Osteoarthritis Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Osteoarthritis Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Osteoarthritis Gene Therapy Revenue
3.4 Global Osteoarthritis Gene Therapy Market Concentration Ratio
3.4.1 Global Osteoarthritis Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Osteoarthritis Gene Therapy Revenue in 2022
3.5 Osteoarthritis Gene Therapy Key Players Head office and Area Served
3.6 Key Players Osteoarthritis Gene Therapy Product Solution and Service
3.7 Date of Enter into Osteoarthritis Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Osteoarthritis Gene Therapy Breakdown Data by Type
4.1 Global Osteoarthritis Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Osteoarthritis Gene Therapy Forecasted Market Size by Type (2024-2029)
5 Osteoarthritis Gene Therapy Breakdown Data by Application
5.1 Global Osteoarthritis Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Osteoarthritis Gene Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Osteoarthritis Gene Therapy Market Size (2018-2029)
6.2 North America Osteoarthritis Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Osteoarthritis Gene Therapy Market Size by Country (2018-2023)
6.4 North America Osteoarthritis Gene Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Osteoarthritis Gene Therapy Market Size (2018-2029)
7.2 Europe Osteoarthritis Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Osteoarthritis Gene Therapy Market Size by Country (2018-2023)
7.4 Europe Osteoarthritis Gene Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Osteoarthritis Gene Therapy Market Size (2018-2029)
8.2 Asia-Pacific Osteoarthritis Gene Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Osteoarthritis Gene Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Osteoarthritis Gene Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Osteoarthritis Gene Therapy Market Size (2018-2029)
9.2 Latin America Osteoarthritis Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Osteoarthritis Gene Therapy Market Size by Country (2018-2023)
9.4 Latin America Osteoarthritis Gene Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Osteoarthritis Gene Therapy Market Size (2018-2029)
10.2 Middle East & Africa Osteoarthritis Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Osteoarthritis Gene Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Osteoarthritis Gene Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Flexion
11.1.1 Flexion Company Detail
11.1.2 Flexion Business Overview
11.1.3 Flexion Osteoarthritis Gene Therapy Introduction
11.1.4 Flexion Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.1.5 Flexion Recent Development
11.2 GeneQuine
11.2.1 GeneQuine Company Detail
11.2.2 GeneQuine Business Overview
11.2.3 GeneQuine Osteoarthritis Gene Therapy Introduction
11.2.4 GeneQuine Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.2.5 GeneQuine Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Osteoarthritis Gene Therapy Introduction
11.3.4 Novartis Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Smith & Nephew
11.4.1 Smith & Nephew Company Detail
11.4.2 Smith & Nephew Business Overview
11.4.3 Smith & Nephew Osteoarthritis Gene Therapy Introduction
11.4.4 Smith & Nephew Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.4.5 Smith & Nephew Recent Development
11.5 Genascence
11.5.1 Genascence Company Detail
11.5.2 Genascence Business Overview
11.5.3 Genascence Osteoarthritis Gene Therapy Introduction
11.5.4 Genascence Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.5.5 Genascence Recent Development
11.6 Kolon TissueGene
11.6.1 Kolon TissueGene Company Detail
11.6.2 Kolon TissueGene Business Overview
11.6.3 Kolon TissueGene Osteoarthritis Gene Therapy Introduction
11.6.4 Kolon TissueGene Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.6.5 Kolon TissueGene Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Osteoarthritis Gene Therapy Introduction
11.7.4 Sanofi Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 Paraxel
11.8.1 Paraxel Company Detail
11.8.2 Paraxel Business Overview
11.8.3 Paraxel Osteoarthritis Gene Therapy Introduction
11.8.4 Paraxel Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.8.5 Paraxel Recent Development
11.9 Medipost
11.9.1 Medipost Company Detail
11.9.2 Medipost Business Overview
11.9.3 Medipost Osteoarthritis Gene Therapy Introduction
11.9.4 Medipost Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.9.5 Medipost Recent Development
11.10 Mundipharma
11.10.1 Mundipharma Company Detail
11.10.2 Mundipharma Business Overview
11.10.3 Mundipharma Osteoarthritis Gene Therapy Introduction
11.10.4 Mundipharma Revenue in Osteoarthritis Gene Therapy Business (2018-2023)
11.10.5 Mundipharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details